novel HDAC6 inhibitor

Novel HDAC6 inhibitors are a class of selective small molecule epigenetic modulators designed to target Histone Deacetylase 6 (HDAC6), a Class IIb deacetylase primarily located in the cytoplasm. Unlike pan-HDAC inhibitors, these compounds are engineered for high selectivity (e.g., approximately 50-fold over HDAC1), targeting non-histone substrates such as alpha-tubulin, HSP90, Ku-70, and peroxiredoxins. Developed through research at Memorial Sloan-Kettering Cancer Center and Columbia University, these inhibitors disrupt cellular processes including protein degradation (aggresome formation), cellular mobility, and oxidative stress responses. Preclinical studies have demonstrated their ability to induce alpha-tubulin acetylation without affecting histone acetylation, showing potential for treating various malignancies—such as prostate cancer, glioblastoma, and lung adenocarcinoma—particularly when used in combination with DNA-damaging agents like etoposide or doxorubicin. They are also under investigation for therapeutic applications in neurodegenerative diseases due to their role in managing misfolded protein pathways.

Other names

HDAC6 inhibitorHDAC-6 inhibitorHDAC 6 inhibitorhistone deacetylase 6 inhibitor